Haas Jigal, Kedem Alon, Machtinger Ronit, Dar Shir, Hourvitz Ariel, Yerushalmi Gil, Orvieto Raoul
Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, Israel.
J Ovarian Res. 2014 Apr 3;7:35. doi: 10.1186/1757-2215-7-35.
Controlled ovarian hyperstimulation (COH) which combining GnRH antagonist co-treatment and GnRH agonist trigger with an additional 1500 IU hCG luteal rescue on day of oocytes retrieval, has become a common tool aiming to reduce severe ovarian hyperstimulation syndrome (OHSS). In the present, proof of concept study, we evaluate whether by deferring the hCG rescue bolus for 3 days, we are still able to rescue the luteal phase.
Patients undergoing the GnRH-antagonist protocol, who were considered at high risk for developing severe OHSS and received GnRH-agonist for final oocyte maturation, were included. For luteal phase support, all patients received an "intense" luteal support. Those who had no signs of early moderate OHSS on day 3 after oocytes retrieval were instructed to inject 1500 IU of HCG bolus (hCG group). Ovarian stimulation characteristics and mid luteal progesterone levels were compared between those who received the HCG bolus and those who did not.
Eleven IVF cycles were evaluated, 5 in the hCG group and 6 in the intense luteal support only group. While no in-between group differences were observed in ovarian stimulation characteristics, significantly higher mid luteal progesterone levels (>127 nmol/L vs 42.1 ± 14.5 nmol/L, respectively) and a non-significant increase in pregnancy rate (40% vs 16.6%, respectively), were observed in those who receive the hCG bolus compared to those who did not.
hCG luteal rescue should be offered 3 days after oocytes retrieval only to those patients with no signs of early moderate OHSS. Further studies are required to elucidate the appropriate regimen of luteal HCG administration in patients undergoing final follicular maturation with GnRH-agonist.
控制性卵巢刺激(COH)联合促性腺激素释放激素(GnRH)拮抗剂共同治疗,并在取卵日额外注射1500IU人绒毛膜促性腺激素(hCG)进行黄体期挽救,已成为旨在降低严重卵巢过度刺激综合征(OHSS)的常用方法。在目前的概念验证研究中,我们评估将hCG挽救推注推迟3天,是否仍能挽救黄体期。
纳入接受GnRH拮抗剂方案、被认为有发生严重OHSS高风险且接受GnRH激动剂进行最终卵母细胞成熟的患者。对于黄体期支持,所有患者均接受“强化”黄体支持。在取卵后第3天无早期中度OHSS迹象的患者被指示注射1500IU hCG推注(hCG组)。比较接受hCG推注和未接受hCG推注患者的卵巢刺激特征和黄体中期孕酮水平。
评估了11个体外受精周期,hCG组5个,仅强化黄体支持组6个。虽然两组在卵巢刺激特征方面未观察到差异,但与未接受hCG推注的患者相比,接受hCG推注的患者黄体中期孕酮水平显著更高(分别为>127nmol/L和42.1±14.5nmol/L),妊娠率有非显著性增加(分别为40%和16.6%)。
仅应对那些无早期中度OHSS迹象的患者在取卵后3天给予hCG黄体期挽救。需要进一步研究以阐明在接受GnRH激动剂进行最终卵泡成熟的患者中黄体期hCG给药的合适方案。